In a move that is generating palpable waves through the biotech industry, Kenai Therapeutics has successfully secured $82 million in funding to advance their trailblazing iPSC-based (induced pluripotent stem cells) drug for Parkinson’s disease into Phase I clinical trials. This impressive financial infusion brings to the forefront the potential of iPSCs as a game-changing therapeutic […]